secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001104659-25-074972
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Ironwood Pharmaceuticals Reports Q2 2025 Results; LINZESS U.S. Net Sales $248M, GAAP Net Income $23.6M
--------------------------------------------------------------------------------

- LINZESS generated $248M in U.S. net sales in Q2 2025, with 10% year-over-year EUTRx demand growth.
- GAAP net income was $23.6M in Q2 2025, compared to a net loss of $0.9M in Q2 2024.
- Adjusted EBITDA was $50.1M in Q2 2025, up from $36.5M in Q2 2024.
- Company plans to align with FDA on confirmatory Phase 3 trial design for apraglutide in Q4 2025.
- Ironwood is actively progressing a strategic alternatives review to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/0001104659-25-074972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/tm2522671d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-074972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer